The natural course of chronic hepatitis B virus infection and its management

Advances in Pharmacology

Volumn 67, Issue , 2013, Pages 247-291

  Hadziyannis, Stephanos J ^a,b   Vassilopoulos, Dimitrios ^b   Hadziyannis, Emilia ^b  

^a HENRY DUNANT HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chronic hepatitis B; HBV; Interferon; Natural course; Nucleos tide analogues; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; BCG VACCINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LEVAMISOLE; NUCLEOSIDE; PREDNISONE; TELBIVUDINE; VIDARABINE PHOSPHATE;

ARTICLE; COMORBIDITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; PATIENT MONITORING; PRIORITY JOURNAL; SHORT COURSE THERAPY;

EID: 84880636445     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-405880-4.00007-X     Document Type: Chapter

References (185)

1. Abdul F., Ndeboko B., Buronfosse T., Zoulim F., Kann M., Nielsen P.E., et al. Potent inhibition of late stages of hepadnavirus replication by a modified cell penetrating Peptide. PLoS One 2012, 7(11):e48721.
2. Antonelli G., Turriziani O. Antiviral therapy: Old and current issues. International Journal of Antimicrobial Agents 2012, 40(2):95-102.
3. Ayoub W.S., Keeffe E.B. Review article: Current antiviral therapy of chronic hepatitis B. Alimentary Pharmacology and Therapeutics 2011, 34(10):1145-1158.
4. Bayer M.E., Blumberg B.S., Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down's Syndrome and hepatitis. Nature 1968, 218(5146):1057-1059.
5. Beck J., Nassal M. Hepatitis B virus replication. World Journal of Gastroenterology 2007, 13(1):48-64.
6. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T., et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. The Journal of Clinical Investigation 2012, 122(2):529-537.
7. Bertoletti A., Maini M.K., Ferrari C. The host-pathogen interaction during HBV infection: Immunological controversies. Antiviral Therapy 2010, 15(Suppl. 3):15-24.
8. Bianchi L., Gudat F. Immunopathology of hepatitis B. Progress in Liver Diseases 1979, 6:371-392.
9. Billioud G., Pichoud C., Puerstinger G., Neyts J., Zoulim F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Research 2011, 92(2):271-276.
10. Blumberg B.S., Alter H.J., Visnich S. A "new" antigen in leukemia sera. JAMA: The Journal of the American Medical Association 1965, 191:541-546.
11. Blumberg B.S., Gerstley B.J., Hungerford D.A., London W.T., Sutnick A.I. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Annals of Internal Medicine 1967, 66(5):924-931.
12. Blumberg B.S., Sutnick A.I., London W.T. Australia antigen and hepatitis. JAMA: The Journal of the American Medical Association 1969, 207(10):1895-1896.
13. Boni C., Laccabue D., Lampertico P., Giuberti T., Vigano M., Schivazappa S., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012, 143(4):963-973. e969.
14. Boni C., Penna A., Bertoletti A., Lamonaca V., Rapti I., Missale G., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. Journal of Hepatology 2003, 39(4):595-605.
15. Bonino F., Piratvisuth T., Brunetto M.R., Liaw Y.F. Diagnostic markers of chronic hepatitis B infection and disease. Antiviral Therapy 2010, 15(Suppl. 3):35-44.
16. Brezillon N., Brunelle M.N., Massinet H., Giang E., Lamant C., DaSilva L., et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One 2011, 6(12):e25096.
17. Brunetto M.R., Giarin M., Saracco G., Oliveri F., Calvo P., Capra G., et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993, 105(3):845-850.
18. Brunetto M.R., Oliveri F., Colombatto P., Coco B., Ciccorossi P., Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. Journal of Hepatology 2003, 39(Suppl. 1):S164-S167.
19. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135(2):459-467.
20. Carman W.F., Jacyna M.R., Hadziyannis S., Karayiannis P., McGarvey M.J., Makris A., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. The Lancet 1989, 2(8663):588-591.
21. Chan H.L., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., et al. Hepatitis B surface antigen quantification: Why and how to use it in 2011-A core group report. Journal of Hepatology 2011, 55(5):1121-1131.
22. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. The New England Journal of Medicine 1997, 336(26):1855-1859.
23. Chang T.T., Lai C.L., Kew Yoon S., Lee S.S., Coelho H.S., Carrilho F.J., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51(2):422-430.
24. Chang T.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010, 52(3):886-893.
25. Chen Y.C., Huang S.F., Chu C.M., Liaw Y.F. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. Journal of Viral Hepatitis 2012, 19(2):138-146.
26. Chen C.J., Yang H.I. Natural history of chronic hepatitis B REVEALed. Journal of Gastroenterology and Hepatology 2011, 26(4):628-638.
27. Chotiyaputta W., Lok A.S. Endpoints of hepatitis B treatment. Journal of Viral Hepatitis 2010, 17(10):675-684.
28. Chu C.M., Hung S.J., Lin J., Tai D.I., Liaw Y.F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. American Journal of Medicine 2004, 116(12):829-834.
29. Chu C.M., Karayiannis P., Fowler M.J., Monjardino J., Liaw Y.F., Thomas H.C. Natural history of chronic hepatitis B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. Hepatology 1985, 5(3):431-434.
30. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up. Hepatology 2007, 45(5):1187-1192.
31. Cohen C., Evans A.A., London W.T., Block J., Conti M., Block T. Underestimation of chronic hepatitis B virus infection in the United States of America. Journal of Viral Hepatitis 2008, 15(1):12-13.
32. Colvin, H. M., Mitchell, A. E., Institute of Medicine (U.S.), Committee on the Prevention and Control of Viral Hepatitis Infections, Institute of Medicine (U.S.), Board on Population Health and Public Health Practice, & National Academies Press (U.S.). (2010). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C (The National Academies Press edn.). Washington, DC: National Academies Press.
33. Cote P.J., Korba B.E., Miller R.H., Jacob J.R., Baldwin B.H., Hornbuckle W.E. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000, 31(1):190-200.
34. De Clercq E. Human viral diseases: What is next for antiviral drug discovery?. Current Opinion in Virology 2012, 2(5):572-579.
35. De Clercq E. Antivirals: Past, present and future. Biochemical Pharmacology 2013, 85:727-744.
36. de Franchis R., Hadengue A., Lau G., Lavanchy D., Lok A., McIntyre N., et al. EASL international consensus conference on hepatitis B. Journal of Hepatology 2003, 39(Suppl. 1):S3-S25.
37. Dienstag J.L. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009, 49(5 Suppl.):S112-S121.
38. Doo E.C., Ghany M.G. Hepatitis B virology for clinicians. Clinics in Liver Disease 2010, 14(3):397-408.
39. Dusheiko G.M., Paterson A.C., Pitcher L., Kassianides C., DiBisceglie A.M., Song E., et al. Recombinant leucocyte interferon treatment of chronic hepatitis B. An analysis of two therapeutic trials. Journal of Hepatology 1986, 3(Suppl. 2):S199-S207.
40. EASL Clinical practice guidelines: Management of chronic hepatitis B. Journal of Hepatology 2009, 50(2):227-242. (Review).
41. EASL Clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology 2012, 57(1):167-185.
42. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273. e1261.
43. Fattovich G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. Journal of Hepatology 2008, 48(2):335-352.
44. Feld J.J., Heathcote E.J. Hepatitis B e antigen-positive chronic hepatitis B: Natural history and treatment. Seminars in Liver Disease 2006, 26(2):116-129.
45. Feld J.J., Wong D.K., Heathcote E.J. Endpoints of therapy in chronic hepatitis B. Hepatology 2009, 49(5 Suppl.):S96-S102.
46. Ferri C., Govoni M., Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Current Opinion in Rheumatology 2010, 22(4):443-450.
47. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49(5 Suppl.):S185-S195.
48. Frenette C.T., Gish R.G. To "be" or not to "be": That is the question. American Journal of Gastroenterology 2009, 104(8):1948-1952.
49. Fung J., Lai C.L., Yuen M.F. To stop or not to stop: The quest for long-term viral suppression. Journal of Gastroenterology and Hepatology 2011, 26(3):420-422.
50. Funk M.L., Rosenberg D.M., Lok A.S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. Journal of Viral Hepatitis 2002, 9(1):52-61.
51. Gara N., Zhao X., Collins M.T., Chong W.H., Kleiner D.E., Jake Liang T., et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Alimentary Pharmacology and Therapeutics 2012, 35(11):1317-1325.
52. Garcia-Sastre A., Biron C.A. Type 1 interferons and the virus-host relationship: A lesson in detente. Science 2006, 312(5775):879-882.
53. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009, 49(4):1335-1374.
54. Giles J.P., McCollum R.W., Berndtson L.W., Krugman S. Relation of Australia-SH antigen to the willowbrook MS-2 strain. The New England Journal of Medicine 1969, 281(3):119-122.
55. Gish R.G., Lok A.S., Chang T.T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133(5):1437-1444.
56. Guo H., Jiang D., Zhou T., Cuconati A., Block T.M., Guo J.T. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: An intermediate of covalently closed circular DNA formation. Journal of Virology 2007, 81(22):12472-12484.
57. Guo Y., Li Y., Mu S., Zhang J., Yan Z. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. Journal of Medical Virology 2009, 81(7):1177-1183.
58. Gupta S.K. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care and STDs 2008, 22(2):99-103.
59. Hadziyannis S.J. Anti-HBe positive chronic active hepatitis 1981, 683. The Franklin Institute Press. W. Szmuness, H.J. Alter, J. Maynard (Eds.).
60. Hadziyannis S.J. Hepatititis B e antigen negative chronic hepatitis B: From clinical recognision to pathogenesis and treatment. Viral Hepatitis Review 1995, 1:7-36.
61. Hadziyannis S.J. New developments in the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy 2006, 6(9):913-921.
62. Hadziyannis S.J. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Expert Opinion on Investigational Drugs 2007, 16(6):777-786.
63. Hadziyannis S.J. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatology International 2007, 1(2):281-284.
64. Hadziyannis S.J. Milestones and perspectives in viral hepatitis B. Liver International 2011, 31(Suppl. 1):129-134.
65. Hadziyannis S.J. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. Journal of Hepatology 2011, 55(1):183-191.
66. Hadziyannis S., Gerber M.A., Vissoulis C., Popper H. Cytoplasmic hepatitis B antigen in "ground-glass" hepatocytes of carriers. Archives of Pathology 1973, 96(5):327-330.
67. Hadziyannis S.J., Lieberman H.M., Karvountzis G.G., Shafritz D.A. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983, 3(5):656-662.
68. Hadziyannis S.J., Merikas G.E., Afroudakis A.P. Hepatitis-associated antigen in chronic liver disease. The Lancet 1970, 1(7663):100.
69. Hadziyannis S., Merikas G., Panetsos S., Kourepi M. Hepatitis associated antigen carriers among blood donors in Greece. American Journal of Diseases of Children 1972, 123(4):381-383.
70. Hadziyannis S.J., Papatheodoridis G.V. Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment. Seminars in Liver Disease 2006, 26(2):130-141.
71. Hadziyannis S., Raimondo G., Papaioannou C., Anastassakos C., Wong D., Sninsky J., et al. Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication. Journal of Hepatology 1987, 5(3):253-259.
72. Hadziyannis S.J., Sevastianos V., Rapti I., Vassilopoulos D., Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitisB who stop long-term treatment with adefovir. Gastroenterology 2012, 143(3):629-636. e621.
73. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. The New England Journal of Medicine 2003, 348(9):800-807.
74. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131(6):1743-1751.
75. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34(4 Pt 1):617-624.
76. Hadziyannis S.J., Vassilopoulos D. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Antiviral Research 2001, 52(2):91-98.
77. Hadziyannis S.J., Vassilopoulos D. Telbivudine in the treatment of chronic hepatitis B. Expert Review of Gastroenterology & Hepatology 2008, 2(1):13-22.
78. Hadziyannis S., Vassilopoulos D. What should be the endpoints of oral therapy in HBeAg-positive versus HBeAg-negative patients with chronic hepatitis B. Current Hepatitis Reports 2012, 11(2):65-69.
79. Hansen B.E., Buster E.H., Steyerberg E.W., Lesaffre E., Janssen H.L. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. Journal of Medical Virology 2010, 82(7):1135-1142.
80. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011, 140(1):132-143.
81. Hirsch M.S. Entecavir surprise. The New England Journal of Medicine 2007, 356(25):2641-2643.
82. Hong S.H., Cho O., Kim K., Shin H.J., Kotenko S.V., Park S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Research 2007, 126(1-2):245-249.
83. Hoofnagle J.H., Alter H.J. Chronic viral hepatitis. Viral hepatitis and liver disease 1984, 97-113. Grune & Statton, Inc., Orlando, Florida. G.N. Vyas, J.L. Dienstag, J.H. Hoofnagle (Eds.).
84. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007, 45(4):1056-1075.
85. Hoofnagle J.H., Dusheiko G.M., Seeff L.B., Jones E.A., Waggoner J.G., Bales Z.B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Annals of Internal Medicine 1981, 94(6):744-748.
86. Hoofnagle J.H., Peters M., Mullen K.D., Jones D.B., Rustgi V., Di Bisceglie A., et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988, 95(5):1318-1325.
87. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. The Lancet 2005, 365(9454):123-129.
88. Jarvis B., Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999, 58(1):101-141.
89. Kaur I., Gupta R.C., Puri M. Ribosome inactivating proteins from plants inhibiting viruses. Virologica Sinica 2011, 26(6):357-365.
90. Keeffe E.B., Dieterich D.T., Pawlotsky J.M., Benhamou Y. Chronic hepatitis B: Preventing, detecting, and managing viral resistance. Clinical Gastroenterology and Hepatology 2008, 6(3):268-274.
91. Kim K.H., Kim N.D., Seong B.L. Discovery and development of anti-HBV agents and their resistance. Molecules 2010, 15(9):5878-5908.
92. Kock J., Rosler C., Zhang J.J., Blum H.E., Nassal M., Thoma C. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathogens 2010, 6(9):e1001082.
93. Krepstakies M., Lucifora J., Nagel C.H., Zeisel M.B., Holstermann B., Hohenberg H., et al. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. The Journal of Infectious Diseases 2012, 205(11):1654-1664.
94. Krugman S., McAuliffe V.J., Purcell R.H. Hepatitis B vaccines: Present status. Seminars in Liver Disease 1981, 1(1):81-87. (Review).
95. Kumar M., Sarin S.K., Hissar S., Pande C., Sakhuja P., Sharma B.C., et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134(5):1376-1384.
96. Lai M., Liaw Y.F. Chronic hepatitis B: Past, present, and future. Clinics in Liver Disease 2010, 14(3):531-546.
97. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. The New England Journal of Medicine 2006, 354(10):1011-1020.
98. Lampertico P., Del Ninno E., Manzin A., Donato M.F., Rumi M.G., Lunghi G., et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997, 26(6):1621-1625.
99. Lampertico P., Del Ninno E., Vigano M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37(4):756-763.
100. Lau G.K. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: A comparison focusing on HBeAg seroconversion. Liver International 2010, 30(4):512-520.
101. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. The New England Journal of Medicine 2005, 352(26):2682-2695.
102. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004, 11(2):97-107.
103. Lee M., Keeffe E.B. Hepatitis B: Modern end points of treatment and the specter of viral resistance. Gastroenterology Clinics of North America 2011, 40(3):495-505.
104. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. Journal of Hepatology 2009, 51(3):581-592.
105. Li L., Chirapu S.R., Finn M.G., Zlotnick A. Phase diagrams map the properties of anti-viral agents directed against hepatitis B virus core assembly. Antimicrobial Agents and Chemotherapy 2013, 57:1505-1508.
106. Liaw Y.F. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver International 2011, 31(Suppl. 1):117-121.
107. Liaw Y.F. Impact of therapy on the outcome of chronic hepatitis B. Liver International 2013, 33(Suppl. 1):111-115.
108. Liaw Y.F., Brunetto M.R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antiviral Therapy 2010, 15(Suppl. 3):25-33.
109. Liaw Y.F., Chu C.M. Hepatitis B virus infection. The Lancet 2009, 373(9663):582-592.
110. Liaw Y.F., Kao Jia-Horng, Piratvisuth Teerha, Chan Henry Lik Yuen, Chien Rong-Nan, Liu Chun-Jen, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology International 2012, 6(3):531-561.
111. Liaw Y.F., Sheen I.S., Lee C.M., Akarca U.S., Papatheodoridis G.V., Suet-Hing Wong F., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53(1):62-72.
112. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. The New England Journal of Medicine 2004, 351(15):1521-1531.
113. Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype: Recent advances. Journal of Gastroenterology and Hepatology 2011, 26(Suppl. 1):123-130.
114. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antiviral Therapy 2010, 15(Suppl. 3):3-14.
115. Lok A.S. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma?. Journal of Gastroenterology and Hepatology 2011, 26(2):221-227.
116. Lok A.S. Hepatitis B: A journey from 1982-2012 2012, http://www.aasld.org.
117. Lok A.S., Hadziyannis S.J., Weller I.V., Karvountzis M.G., Monjardino J., Karayiannis P., et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984, 25(11):1283-1287.
118. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000-Summary of a workshop. Gastroenterology 2001, 120(7):1828-1853.
119. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45(2):507-539.
120. Lok A.S., McMahon B.J. Chronic hepatitis B: Update 2009. Hepatology 2009, 50(3):661-662.
121. Lok, A. S., & McMahon, B. J. (2009). Chronic hepatitis B: Update 2009. AASLD Practice Guidelines. Retrieved from http://www.aasld.org.website.
122. Lok A.S., Trinh H., Carosi G., Akarca U.S., Gadano A., Habersetzer F., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012, 143(3):619-628. e611.
123. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., et al. Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46(1):254-265.
124. Lucifora J., Esser K., Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Research 2012, 97:195-197.
125. Magnius L.O., Espmark A. A new antigen complex co-occurring with Australia antigen. Acta Pathologica et Microbiologica Scandinavica. Section B: Microbiology and Immunology 1972, 80(2):335-337.
126. Mailliard M.E., Gollan J.L. Suppressing hepatitis B without resistance-So far, so good. The New England Journal of Medicine 2003, 348(9):848-850.
127. Manesis E.K., Hadziyannis S.J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121(1):101-109.
128. Manesis E.K., Papatheodoridis G.V., Sevastianos V., Cholongitas E., Papaioannou C., Hadziyannis S.J. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. American Journal of Gastroenterology 2003, 98(10):2261-2267.
129. Marcellin P., Chang T.T., Lim S.G., Sievert W., Tong M., Arterburn S., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48(3):750-758.
130. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. The Lancet 2013, 381:468-475.
131. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. The New England Journal of Medicine 2008, 359(23):2442-2455.
132. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. The New England Journal of Medicine 2004, 351(12):1206-1217.
133. Maupas P., Chiron J.P., Barin F., Coursaget P., Goudeau A., Perrin J., et al. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). The Lancet 1981, 1(8215):289-292.
134. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(5 Suppl.):S45-S55.
135. McMahon B.J., Block J., Haber B., London T., McHugh J.A., Perrillo R., et al. Internist diagnosis and management of chronic hepatitis B virus infection. American Journal of Medicine 2012, 125(11):1063-1067.
136. McMahon B.J., Bulkow L.R., Singleton R.J., Williams J., Snowball M., Homan C., et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011, 54(3):801-807.
137. Milich D.R. Molecular and genetic aspects of the immune responses to hepatitis B viral antigens. Advances in Experimental Medicine and Biology 1989, 257:115-133. (Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review).
138. Milich D.R. Immune response to hepatitis B virus proteins: Relevance of the murine model. Seminars in Liver Disease 1991, 11(2):93-112.
139. Mulkay J.P. Hepatitis B: Screening and treatment. Revue Médicale de Bruxelles 2012, 33(4):215-222.
140. Nassal M. New insights into HBV replication: New opportunities for improved therapies. Future Virology 2009, 4(1):55-70.
141. Ono A., Suzuki F., Kawamura Y., Sezaki H., Hosaka T., Akuta N., et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. Journal of Hepatology 2012, 57(3):508-514.
142. Ott J.J., Stevens G.A., Groeger J., Wiersma S.T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012, 30(12):2212-2219.
143. Pagliaccetti N.E., Chu E.N., Bolen C.R., Kleinstein S.H., Robek M.D. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010, 401(2):197-206.
144. Pan C.Q., Tong M., Kowdley K.V., Hu K.Q., Chang T.T., Lai C.L., et al. High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clinical Gastroenterology and Hepatology 2012, 10(9):1047-1050. e1041.
145. Papatheodoridis G.V., Manolakopoulos S., Liaw Y.F., Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. Journal of Hepatology 2012, 57(1):196-202.
146. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49(5 Suppl.):S103-S111.
147. Perrillo R., Hou J., Papatheodoridis G., Manns M. Patient management and clinical decision making in HBV-Aims of therapy and what we can achieve. Antiviral Therapy 2010, 15(Suppl. 3):45-51.
148. Peters M.G. Special populations with hepatitis B virus infection. Hepatology 2009, 49(5 Suppl.):S146-S155.
149. Pollicino T., Raffa G., Santantonio T., Gaeta G.B., Iannello G., Alibrandi A., et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. Journal of Virology 2011, 85(1):432-439.
150. Rapti I., Dimou E., Mitsoula P., Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45(2):307-313.
151. Rapti I.N., Hadziyannis S.J. Treatment of special populations with chronic hepatitis B infection. Expert Review of Gastroenterology & Hepatology 2011, 5(3):323-339.
152. Schieck A., Schulze A., Gahler C., Muller T., Haberkorn U., Alexandrov A., et al. Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology 2013, Jan 4., [Epub ahead of print]. 10.1002/hep.26211.
153. Schiff E., Simsek H., Lee W.M., Chao Y.C., Sette H., Janssen H.L., et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. American Journal of Gastroenterology 2008, 103(11):2776-2783.
154. Seto W.K., Fung J., Yuen M.F., Lai C.L. Future prevention and treatment of chronic hepatitis B infection. Journal of Clinical Gastroenterology 2012, 46(9):725-734.
155. Shafritz D.A., Shouval D., Sherman H.I., Hadziyannis S.J., Kew M.C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. The New England Journal of Medicine 1981, 305(18):1067-1073.
156. Sheng Y.J., Liu J.Y., Tong S.W., Hu H.D., Zhang D.Z., Hu P., et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: A systematic review and meta-analysis. Virology Journal 2011, 8:393.
157. Sherlock S., Fox R.A., Niazi S.P., Scheuer P.J. Chronic liver disease and primary liver-cell cancer with hepatitis-associated (Australia) antigen in serum. The Lancet 1970, 1(7659):1243-1247.
158. Sonneveld M.J., Rijckborst V., Zeuzem S., Heathcote E.J., Simon K., Senturk H., et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2012, 56(1):67-75.
159. Sonneveld M.J., Wong V.W., Woltman A.M., Wong G.L., Cakaloglu Y., Zeuzem S., et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142(3):513-520. e511.
160. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. The New England Journal of Medicine 1980, 303(15):833-841.
161. Szpakowski J.L., Tucker L.Y. Causes of death in patients with hepatitis B: A natural history cohort study in the United States. Hepatology 2012, Oct 18., [Epub ahead of print]. 10.1002/hep.26110.
162. Tana M.M., Hoofnagle J.H. Scar undone: Long-term therapy of hepatitis B. The Lancet 2013, 381:433-434.
163. Thai H., Campo D.S., Lara J., Dimitrova Z., Ramachandran S., Xia G., et al. Convergence and coevolution of hepatitis B virus drug resistance. Nature Communications 2012, 3:789.
164. Thimme R., Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?. Journal of Hepatology 2012, 58:205-209.
165. Thomas H.C., Scully L.J., McDonald J.A. Lymphoblastoid and recombinant alpha-A interferon therapy of chronic hepatitis B virus infection. The Royal Free Hospital experience. Journal of Hepatology 1986, 3(Suppl. 2):S193-S197.
166. Thomas D., Zoulim F. New challenges in viral hepatitis. Gut 2012, 61(Suppl. 1):i1-i5.
167. Tong M.J., Hsien C., Hsu L., Sun H.E., Blatt L.M. Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States. Hepatology 2008, 48(4):1070-1078.
168. Vassiliadis T.G., Giouleme O., Koumerkeridis G., Koumaras H., Tziomalos K., Patsiaoura K., et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: A 4-year study. Journal of Gastroenterology and Hepatology 2010, 25(1):54-60.
169. Vassilopoulos D., Hadziyannis S.J. Chronic hepatitis B and D. Practical management of liver diseases 2008, 26-38. Cambridge University Press, Cambridge, New York. Z.M. Younossi (Ed.).
170. Vassilopoulos D., Hadziyannis S.J. Current treatment options for HBV infection. Current Hepatitis Reports 2009, 8(1):26-30.
171. Volz T., Allweiss L., M' Barek M.B., Warlich M., Lohse A.W., Pollok J.M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology 2013, 58:861-867.
172. Wang Y.X., Zheng S.M., Zhang Y., Qin J.P., Lin H., Liu X.C., et al. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa. Scandinavian Journal of Gastroenterology 2013, 48:213-217.
173. Wasley A., Kruszon-Moran D., Kuhnert W., Simard E.P., Finelli L., McQuillan G., et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. The Journal of Infectious Diseases 2010, 202(2):192-201.
174. Weller I.V., Fowler M.J., Monjardino J., Carreno V., Thomas H.C., Sherlock S. Inhibition of hepatitis B viral replication by lymphoblastoid interferon. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 1982, 299(1094):128-130.
175. Wen Y.M., Lin X., Ma Z.M. Exploiting new potential targets for anti-hepatitis B virus drugs. Current Drug Targets. Infectious Disorders 2003, 3(3):241-246. (Review).
176. WHO Hepatitis B: fact sheet. no. 204 Retrieved from. http://www.who.int/mediacentre/factsheets/fs204/en/.
177. Wong V.W., Sung J.J. Diagnosis and personalized management of hepatitis B including significance of genotypes. Current Opinion in Infectious Diseases 2012, 25(5):570-577.
178. Yim H.J., Lok A.S. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006, 43(2 Suppl. 1):S173-S181.
179. Yuen M.F., Lai C.L. Treatment of chronic hepatitis B: Evolution over two decades. Journal of Gastroenterology and Hepatology 2011, 26(Suppl. 1):138-143.
180. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008, 26(49):6266-6273.
181. Zhang Y.L., Cheng T., Cai Y.J., Yuan Q., Liu C., Zhang T., et al. RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo. BMC Microbiology 2010, 10:214.
182. Zhang X., Kraft A., Broering R., Schlaak J.F., Dittmer U., Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opinion on Drug Discovery 2012, 7(7):597-611.
183. Zhang F.K., Liu D.G., Jia J.D. Antiviral therapy for hepatitis B in special populations. Antiviral Therapy 2010, 15(8):1067-1075.
184. Zheng L., Wang Q., Yang X., Guo X., Chen L., Tao L., et al. Antiviral activity of FNC, 2'-deoxy-2'-beta-fluoro-4'-azidocytidine, against human and duck HBV replication. Antiviral Therapy 2012, 17(4):679-687.
185. Zoulim F., Locarnini S. Management of treatment failure in chronic hepatitis B. Journal of Hepatology 2012, 56(Suppl. 1):S112-S122.